Ark Genomic Revolution ETF

Quinn Emanuel Fined $3M and Mandated Training for Misleading Court in Natera Case

Beam Therapeutics Presents BEAM-302 Phase 1/2 Data, Plans Accelerated Approval in 2026

Manulife Singapore to Launch Shield™ Multi-Cancer Test with Guardant Health in May 2026

Tempus AI to participate in the 2026 ASCO® Annual Meeting

Tempus AI will host an Investor Day on May 29, 2026

Tempus AI will hold its Annual General Meeting on May 21, 2026

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Tempus AI to Hold Annual General Meeting on May 20, 2026

Tempus AI to Host Inaugural Investor Day on May 29, 2026

Tempus AI Expands Strategic Collaboration with Bristol Myers Squibb in Oncology and Neuroscience

Illumina CEO joins China delegation, stock price rises

Tempus AI is expected to close its upsized $400 million convertible senior notes offering on May 12

Intellia Therap released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 15.05 M (forecast USD 13.81 M), actual EPS USD -0.8121 (forecast USD -0.8904)

ARK Invest Purchases Over $8 Million Worth of Tempus AI (TEM) Stock

H.C. Wainwright cuts Tempus AI (TEM) stock price target on wider losses

Guardant Health Reports Significant Losses in Q4 2025 Earnings

QRG Capital Management Inc. Significantly Increased Holdings in Natera Inc.

The Motley Fool names Tempus AI as a stock poised to disrupt the healthcare market

Beam Therapeutics released FY2026 Q1 earnings on May 7, 2026 (EST), with actual revenue of USD 31.74 M (forecast USD 12.22 M) and actual EPS of USD -0.9133 (forecast USD -1.0121)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IMNN

ARKG

IBBQ

SBIO

LABU

Imunon, Inc. held its Q1 earnings call, highlighting clinical advancements with IMNN-001, which shows promising survival data. However, management expressed concerns over rising cash burn and capital market challenges. The pivotal OVATION III trial is underway, with a focus on minimizing shareholder dilution through strategic financing. Despite strong investigator interest, the lengthy timeline for data and regulatory submission poses risks for investors. The company aims to present detailed efficacy data at an upcoming R&D Day in 2026.

Tip Ranks

Imunon

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Imunon Earnings Call Balances Breakthroughs and Cash Strain

RNXT

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

RenovoRx

SPDR S&P Health Equip

iShares Global Healthcare

VG Health

iShares US Medical Devices

RenovoRx Earnings Call Signals Commercial Inflection

510660

Antengene Corporation has appointed Dr. Bing Hou as Chief Scientific Officer to enhance its R&D strategy and advance its next-generation therapeutic pipeline. Dr. Hou, who has been with Antengene since 2019, will lead efforts in Drug Discovery and Translational Medicine. His leadership is expected to strengthen the company's proprietary platforms, including the AnTenGager® T-cell engager platform, and support the development of innovative therapies for autoimmune diseases and cancers.

PR Newswire

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

ANTENGENE-B

UCB S.A.

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

BBIO

BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Citi, BridgeBio Pharma also received a Hold from J.P. Morgan’s Eric Joseph in a report issued today. However, on May 13, Bank of America Securities reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO).

Bridgebio Pharma

Direxion S&P Biotech Bear 3X

Citigroup

JPMorgan Chase

Bank of America

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BridgeBio Pharma (BBIO) Gets a Hold from Citi

ERAS

RVMD

Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) regarding possible violations of federal securities laws following a patent infringement allegation from Revolution Medicines. This news caused Erasca's stock to drop by approximately 48%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Erasca

Revolution Medicines

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

PHVS

Pharvaris Chief Commercial Officer Wim Souverijns sold 10,000 shares on May 15 for $299,163 at a weighted average price of $29.92. Following the transaction, he holds 45,111 shares.

PUBT

Pharvaris BV

Pharvaris Chief Commercial Officer Wim Souverijns sells 10,000 shares for $299,163

DVAX

VXRT

Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.

TradingView

Dynavax Tech

Vaxart

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

Charles River Laboratories International Inc. (CRL) shares rose 1.67% to $152.43, breaking a four-day losing streak, despite a poor overall market day. The S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. CRL's stock remains 33.40% below its 52-week high of $228.88. Competitors had mixed results, with Labcorp down 0.74% and Alnylam Pharmaceuticals and Bio-Techne rising 2.81% and 2.34%, respectively.

MarketWatch Automated

Charles River Laboratorie

iShares Genomics Immunology and Healthcare ETF

S&P 500

Dow Jones Industrial Average

Labcorp

Alnylam Pharma

Bio-Techne

Factset Research

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

ADAG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Market Beat

Adagene

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

ETON

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

Eton Pharmaceuticals

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

Ark Genomic Revolution ETF(ARKG.US)